JPMorgan Chase & Co. Boosts Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

JPMorgan Chase & Co. boosted its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 431.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,491 shares of the biotechnology company's stock after purchasing an additional 66,982 shares during the quarter. JPMorgan Chase & Co. owned about 0.56% of Anika Therapeutics worth $1,358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ANIK. Capital Management Corp VA grew its position in shares of Anika Therapeutics by 12.1% in the 4th quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company's stock worth $5,358,000 after buying an additional 35,195 shares during the last quarter. Barclays PLC grew its holdings in Anika Therapeutics by 66.6% in the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company's stock worth $806,000 after purchasing an additional 13,054 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Anika Therapeutics by 20.8% during the fourth quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company's stock worth $832,000 after purchasing an additional 8,711 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Anika Therapeutics by 54.1% during the 3rd quarter. Jane Street Group LLC now owns 24,351 shares of the biotechnology company's stock valued at $601,000 after purchasing an additional 8,550 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Anika Therapeutics by 9.3% in the 4th quarter. American Century Companies Inc. now owns 29,891 shares of the biotechnology company's stock worth $492,000 after purchasing an additional 2,553 shares in the last quarter. 91.53% of the stock is currently owned by institutional investors.

Anika Therapeutics Price Performance

NASDAQ:ANIK traded down $0.10 during midday trading on Thursday, hitting $14.43. The company's stock had a trading volume of 3,556 shares, compared to its average volume of 69,284. Anika Therapeutics, Inc. has a fifty-two week low of $12.48 and a fifty-two week high of $29.12. The firm's 50 day moving average is $15.26 and its 200-day moving average is $17.06. The firm has a market cap of $206.94 million, a P/E ratio of -2.17 and a beta of 0.82.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.13). The company had revenue of $30.60 million during the quarter, compared to analysts' expectations of $29.00 million. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. As a group, analysts forecast that Anika Therapeutics, Inc. will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

ANIK has been the topic of a number of research analyst reports. B. Riley began coverage on Anika Therapeutics in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Barrington Research dropped their target price on shares of Anika Therapeutics from $25.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, March 13th. Finally, StockNews.com raised shares of Anika Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, March 13th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.